Corvus Pharmaceuticals Files 8-K

TL;DR

CRVS filed an 8-K, looks like a new deal or financials are out.

AI Summary

Corvus Pharmaceuticals, Inc. filed an 8-K on October 23, 2024, reporting an entry into a material definitive agreement and financial statements. The filing does not disclose specific details of the agreement or financial figures within the provided text.

Why It Matters

This filing indicates a significant event or agreement for Corvus Pharmaceuticals, Inc., which could impact its business operations and financial standing.

Risk Assessment

Risk Level: low — The filing is a standard 8-K report and does not contain information that inherently suggests high risk.

Key Players & Entities

• Corvus Pharmaceuticals, Inc. (company) — Registrant
• October 22, 2024 (date) — Earliest event reported
• October 23, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• Burlingame, CA (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market
• $33,833.33 — Commencement Date and will initially be $33,833.33 per month, up to monthly base rent of $
• $47,200.00 — 3 per month, up to monthly base rent of $47,200.00 during the third year of the Lease. In
• $231,234.99 — nsent, the Company will pay Sublandlord $231,234.99 in prepaid rent, which shall be applied

Filing Documents

• crvs-20241022x8k.htm (8-K) — 42KB
• crvs-20241022xex10d1.htm (EX-10.1) — 212KB
• 0001558370-24-013518.txt ( ) — 412KB
• crvs-20241022.xsd (EX-101.SCH) — 3KB
• crvs-20241022_lab.xml (EX-101.LAB) — 15KB
• crvs-20241022_pre.xml (EX-101.PRE) — 10KB
• crvs-20241022x8k_htm.xml (XML) — 5KB

01. Entry into Material Definitive Agreement

Item 1.01. Entry into Material Definitive Agreement. On October 22, 2024, Corvus Pharmaceuticals, Inc. , a Delaware corporation (the " Company ") entered into a sub-sublease agreement (the " Lease ") with NewLimit, Inc., a Delaware corporation (the " Sublandlord "), pursuant to which the Company will lease approximately 20,916 square feet of office space located at 901 Gateway Boulevard, South San Francisco, California 94080 (the " Premises "). The Premises is the subject of a sublease agreement by and between Theravance Biopharma US, Inc. (" Prime Sublandlord ") and Sublandlord, dated May 5, 2022, as amended, and a master lease agreement by and between HMS Gateway Office L.P., predecessor-in-interest to ARE-901/951 Gateway Boulevard, LLC (" Master Landlord") and Theravance, Inc., predecessor-in-interest to Prime Sublandlord, dated as of January 1, 2001, as amended. The term of the Lease will commence on the later of (1) the date that a written consent is received from Master Landlord and Prime Sublandlord (the " Consent "), and (2) February 1, 2025 (the " Commencement Date "). The Company's obligation for the payment of base rent (" Monthly Base Rent ") for the Premises begins on the Commencement Date and will initially be $33,833.33 per month, up to monthly base rent of $47,200.00 during the third year of the Lease. In addition to base rent, the Company is obligated under the Lease to pay its proportionate share of taxes, insurance and operating expenses. Within five business days of the later of the full execution and delivery of the Lease and the Company's receipt of a copy of the fully executed Consent, the Company will pay Sublandlord $231,234.99 in prepaid rent, which shall be applied to the Monthly Base Rent and the Company's proportionate share of additional expenses for the first three months of the term of the Lease. The Lease has a term of three years, measured from the Commencement Date, and the Company has the option to extend the term of the Lease f

01.Financial Statements and Exhibits

Item 9.01.Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Sub-Sublease, by and between NewLimit, Inc. and Corvus Pharmaceuticals, Inc., dated as of October 22, 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL Document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORVUS PHARMACEUTICALS, INC. Date: October 23, 2024 By: /s/ Leiv Lea Leiv Lea Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR